Efficacy and Safety of Fixed-dose Combination Therapy With Telmisartan and Rosuvastatin in Korean Patients With Hypertension and Dyslipidemia: TELSTA-YU (TELmisartan-rosuvaSTAtin from YUhan), a Multicenter, Randomized, 4-arm, Double-blind, Placebo-controlled, Phase III Study

Effectiveness of Telmisartan on Blood Pressure Control in Hypertensive Patients in India: A Real-World Retrospective Study from Electronic Medical Records

“…This recommendation is supported by previous evidence of the efficacy and safety of telmisartan in these populations. Multiple studies have reported that telmisartan monotherapy or in combination with other AHDs significantly reduces and normalizes BP in adults with hypertension and comorbid diabetes and/or metabolic syndrome [26][27][28][29]. Moreover, a recent meta-analysis reported that telmisartan was superior to other ARBs in improving insulin resistance and reducing fasting blood glucose and insulin levels [30], probably due to the pleiotropic effects of telmisartan on the peroxisome proliferator-activated receptor c [31].…”

Fixed‐dose combinations of lipid‐lowering and antihypertensive agents: The way forward?

“…[7][8][9][10] In contrast, there are limited data regarding the effects on BP and LDL-C levels of fixed-dose combinations of rosuvastatin and antihypertensive agents. [11][12][13] Since rosuvastatin induces the largest reductions in LDL-C levels among statins, including this agent in a fixed-dose combination with antihypertensive agents might represent a useful tool in achieving LDL-C targets, particularly in high-risk patients. 14 15 In this double-blind, multicenter trial, 106 hypertensive patients with dyslipidemia were randomly assigned to receive a fixed-dose combination of rosuvastatin 20 mg and amlodipine 10 mg, monotherapy with rosuvastatin 20 mg, or monotherapy with amlodipine 10 mg once daily for 8 weeks.…”

“…All these studies showed that fixed‐dose combinations result in similar reductions in blood pressure (BP) and LDL‐C levels compared with separate pill regimens . In contrast, there are limited data regarding the effects on BP and LDL‐C levels of fixed‐dose combinations of rosuvastatin and antihypertensive agents . Since rosuvastatin induces the largest reductions in LDL‐C levels among statins, including this agent in a fixed‐dose combination with antihypertensive agents might represent a useful tool in achieving LDL‐C targets, particularly in high‐risk patients .…”

“…7-10 In contrast, there are limited data regarding the effects on BP and LDL-C levels of fixed-dose combinations of rosuvastatin and antihypertensive agents. [11][12][13] Since rosuvastatin induces the largest reductions in LDL-C levels among statins, including this agent in a fixed-dose combination with antihypertensive agents might represent a useful tool in achieving LDL-C targets, particularly in high-risk patients. 14 Therefore, the findings of the study by Kim et al, reported in this issue of the Journal of Clinical Hypertension, have important implications.…”

“…15 The findings of the study by Kim et al further strengthen the results of previous studies, which showed that fixed-dose combination of statins and antihypertensive agents is similarly effective and safe with monotherapy. [7][8][9][10][11][12][13]15 It is well-established that despite the availability of several effective and safe classes of antihypertensive agents, less than one third of patients with treated hypertension have controlled blood pressure. 3 Accordingly, among patients with hypercholesterolemia who are receiving lipid-lowering treatment, LDL-C targets are achieved in approximately two thirds of patients.…”